SHEBA MEDICAL CENTER
🇿🇦South Africa
- Country
- 🇿🇦South Africa
- Ownership
- Private
- Established
- 1948-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sheba.co.il
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 75
- Registration Number
- NCT05243212
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
Fourth COVID-19 Vaccine Dose- mRNA1273
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 1000
- Registration Number
- NCT05230953
- Locations
- 🇮🇱
Sheba Medical Center, Ramat-Gan, Israel
Fourth BNT162b2 COVID-19 Vaccine Dose
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 1000
- Registration Number
- NCT05231005
- Locations
- 🇮🇱
Sheba Medical Center, Ramat-Gan, Israel
Study for Detection of Donor-derived Cell-free DNA After Renal Transplantation Using Devysers NGS-based Chimerism Assay.
- Conditions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05226936
Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT05106504
- Locations
- 🇮🇱
Sheba Medical Center, Ramat-Gan, Israel
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT05088889
- Locations
- 🇮🇱
Sheba Medical Centre, Ramat Gan, Israel
Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT05075499
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT05000710
- Locations
- 🇮🇱
Sheba Medical Centre, Ramat Gan, Israel
Bisantrene Combination for Resistant AML
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT04989335
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
Outcome Measures of Pulsed Radiofrequency of the Genicular Nerves When Performed With and Without Concomitant Local Corticosteroid Administration
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT04940832
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
© Copyright 2024. All Rights Reserved by MedPath